Praxis Precision Medicines, Inc. (PRAX) News
Track canonical SquawkNews coverage tagged to PRAX, Praxis Precision Medicines, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Thursday. Shares of Motorola Solutions In c (NYSE: MSI ) rose sharply after the company reported better-than-expected second-quarter financial
EARNINGS | Aug 06, 2026, 02:01 PM UTC
L
PRAX - Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
PRAX - Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 06, 2026, 12:01 PM UTC
L
PRAX - Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
PRAX - Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
EARNINGS | Jul 30, 2026, 08:02 PM UTC
M
Praxis Precision Medicines Announces FDA Extends PDUFA Date To December 27, 2026 For Relutrigine Following Major Amendment Submission; No Ne
FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX ), a fully integrated, leading central nervous system (CNS) precision neuroscience
REGULATION | Jun 29, 2026, 08:35 PM UTC
H
PRAX Seeks Faster Development
Praxis Precision Medicines' seizure drug elsunersen receives Breakthrough Therapy Designation from the FDA after positive trial results
EQUITY | Jun 22, 2026, 05:29 PM UTC
H
PRAX: FDA Grants Breakthrough Therapy
Praxis Precision Medicines receives Breakthrough Therapy designation from FDA for Elsunersen to treat seizures associated with SCN2A development and epileptic encephalopathy
REGULATION | Jun 22, 2026, 12:10 PM UTC
H
PRAX Receives FDA Breakthrough
Praxis Precision Medicines receives FDA Breakthrough Therapy Designation for Elsunersen to treat seizures associated with SCN2A developmental and epileptic encephalopathy
EQUITY | Jun 22, 2026, 12:02 PM UTC